TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP
- TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability
- Following the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP (a rare micro-thrombotic disorder) in the second half of 2025
Utrecht, the Netherlands, 19 December 2024 – TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces the start of clinical development with the dosing of the first participant with TGD001.
